
Accuray Introduces Cenos™ Online Adaptive Therapy Option at ASTRO 2023
Accuray Incorporated, a leading provider of innovative radiotherapy solutions, has announced a pending 510(k) submission for its online adaptive therapy option, Cenos™, designed for use with the Radixact® System. This new solution was introduced in partnership with Limbus AI during the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting held in San Diego, California, from October 1 to 4, 2023.
Approximately 50% of all cancer patients require treatment with radiotherapy, and the dynamic nature of tumors and the changing anatomy of patients during treatment present unique challenges. During radiation treatments, tumors can change in size, shape, or location, and their proximity to healthy tissues may shift due to weight fluctuations in patients. Accuray already offers real-time adaptive therapy through its proprietary Synchrony® technology and offline adaptive therapy with PreciseART® radiotherapy to account for some anatomical changes during radiation delivery. The new Cenos™, platform is designed to further enhance adaptive therapy by allowing medical care teams to make real-time adjustments to treatment plans while the patient is on the treatment table.
Cenos™ will allow radiation oncologists and their teams to quickly and efficiently modify treatment plans as needed, ensuring that patients receive the most effective care possible. It offers a comprehensive adaptive toolset, providing healthcare professionals with flexibility in optimizing and streamlining the workflow for each patient, ultimately leading to better clinical outcomes.
One of the key components of the planning process in radiation therapy is contouring, which involves defining the borders of tumors and organs at risk. This step is labor-intensive and time-consuming, making it a bottleneck in the treatment planning process. Accuray recognized the need for automation in contouring and partnered with Limbus AI to develop tools that would make online adaptive therapy practical for radiotherapy clinics of all sizes. Limbus AI’s contouring technology, known as Limbus Contour, is an AI-based solution that has been adopted by more than 250 clinics worldwide. Integrating this technology into Cenos™ will accelerate the contouring process, ensuring accurate and fast contouring—essential for the real-world clinical implementation of adaptive treatment.
Suzanne Winter, President and CEO of Accuray, expressed pride in the collaboration with Limbus and the development of Cenos™, stating, “The goal of Cenos™ is to provide our customers with a comprehensive and efficient approach to adaptive radiotherapy that includes a solution for making online adaptive therapy feasible for any interested Radixact customer.” She emphasized Accuray’s commitment to evolving radiation delivery systems to facilitate more personalized care for cancer patients.